• Search History (Register)
  • MeSH Browser
  • [Clear]
    • English

Welcome to the international HTA database


Showing [17098 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2025     NIHR Health Technology Assessment programme Methylphenidate versus placebo for fatigue in patients with advanced cancer: the MePFAC randomised controlled trial
2025     NIHR Health Technology Assessment programme Outcomes of specialist physiotherapy for functional motor disorder: the Physio4FMD RCT
2025     NIHR Health Services and Delivery Research programme A digital intervention to improve mental health and interpersonal resilience for young people who have experienced online sexual abuse: the i-Minds non-randomised feasibility clinical trial and nested qualitative study
2025     NIHR Health Services and Delivery Research programme Evaluation of the NHS England Low-Calorie Diet implementation pilot: a coproduced mixed-method study
2025     NIHR Health Technology Assessment programme Cessation of smoking in people attending UK emergency departments: the COSTED RCT with economic and process evaluation
2025     NIHR Health Services and Delivery Research programme Centralisation of specialised healthcare services: a scoping review of definitions, types, and impact on outcomes
2025     National Institute for Health and Care Excellence (NICE) Pulsed–field ablation for atrial fibrillation. NICE interventional procedures guidance 806
2025     National Institute for Health and Care Excellence (NICE) Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over. NICE technology appraisal guidance 1077
2025     National Institute for Health and Care Excellence (NICE) Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 1076
2025     National Institute for Health and Care Excellence (NICE) Dapagliflozin for treating chronic kidney disease. NICE technology appraisal guidance 1075
2025     National Institute for Health and Care Excellence (NICE) Mirikizumab for previously treated moderately to severely active Crohn's disease. NICE technology appraisal guidance 1080
2025     National Institute for Health and Care Excellence (NICE) Zanubrutinib for treating relapsed or refractory mantle cell lymphoma. NICE technology appraisal guidance 1081
2025     National Institute for Health and Care Excellence (NICE) Fruquintinib for previously treated metastatic colorectal cancer. NICE technology appraisal guidance 1079
2025     National Institute for Health and Care Excellence (NICE) Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal). NICE technology appraisal guidance 1084
2025     National Institute for Health and Care Excellence (NICE) Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment when a stem cell transplant is unsuitable (terminated appraisal). NICE technology appraisal guidance 1083
2025     National Institute for Health and Care Excellence (NICE) Letermovir for preventing cytomegalovirus infection after a kidney transplant (terminated appraisal). NICE technology appraisal guidance 1082
2025     National Institute for Health and Care Excellence (NICE) Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over. NICE technology appraisal guidance 1085
2025     NIHR Health Technology Assessment programme Feasibility, acceptability and appropriateness of laparoscopic versus abdominal hysterectomy for women and healthcare professionals: the LAVA trial qualitative process evaluation
2025     Health Information and Quality Authority (HIQA) Retiring a clinical guideline: rapid scoping review
2025     Health Information and Quality Authority (HIQA) Magnetic resonance-guided radiotherapy (MRgRT) evidence synthesis to support a generic justification decision
2025     NIHR Health Technology Assessment programme Digital augmentation of aftercare for patients with anorexia nervosa: the TRIANGLE RCT and economic evaluation
2025     NIHR Health Services and Delivery Research programme Understanding patient pathways to Mother and Baby Units: a longitudinal retrospective service evaluation in the UK
2025     NIHR Health Technology Assessment programme Variation within and between digital pathology and light microscopy for the diagnosis of histopathology slides: blinded crossover comparison study
2025     NIHR Health Services and Delivery Research programme Consequences, costs and cost-effectiveness of workforce configurations in English acute hospitals
2025     NIHR Health Technology Assessment programme Melatonin versus midazolam in the premedication of anxious children attending for elective surgery under general anaesthesia: the MAGIC non-inferiority RCT
2025     NIHR Health Technology Assessment programme Invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms: FUTURE, a superiority RCT and economic evaluation
2025     NIHR Health Technology Assessment programme The risks, benefits, and resource implications of different diets in gastrostomy-fed children: The YourTube mixed method study
2025     NIHR Health Technology Assessment programme Urodynamics tests for the diagnosis and management of male bladder outlet obstruction: long-term follow-up of the UPSTREAM non-inferiority RCT
2025     NIHR Health Technology Assessment programme Ambulatory oxygen for pulmonary fibrosis (OxyPuF): a randomised controlled trial and acceptability study
2025     NIHR Health Technology Assessment programme Challenges to overcome in a randomised trial for Proper Understanding of Recurrent Stress Urinary Incontinence Treatment in women: the PURSUIT RCT
2025     NIHR Health Technology Assessment programme Identifying optimal primary prevention interventions for major cardiovascular disease events and all-cause mortality: a systematic review and hierarchical network meta-analysis of RCTs
2025     National Institute for Health and Care Excellence (NICE) Laparoscopic insertion of an inactive implant for gastro-oesophageal reflux disease. NICE interventional procedures guidance 803
2025     National Institute for Health and Care Excellence (NICE) Targeted muscle reinnervation for managing limb amputation pain. NICE interventional procedures guidance 804
2025     National Institute for Health and Care Excellence (NICE) Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation. NICE interventional procedures guidance 805
2025     National Institute for Health and Care Excellence (NICE) Somapacitan for treating growth hormone deficiency in people 3 to 17 years. NICE technology appraisal guidance 1066
2025     National Institute for Health and Care Excellence (NICE) Efgartigimod for treating antibody-positive generalised myasthenia gravis. NICE technology appraisal guidance 1069
2025     National Institute for Health and Care Excellence (NICE) Linzagolix for treating symptoms of endometriosis. NICE technology appraisal guidance 1067
2025     National Institute for Health and Care Excellence (NICE) Spesolimab for treating generalised pustular psoriasis flares. NICE technology appraisal guidance 1070
2025     National Institute for Health and Care Excellence (NICE) Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 1072
2025     National Institute for Health and Care Excellence (NICE) Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer. NICE technology appraisal guidance 1071
2025     National Institute for Health and Care Excellence (NICE) Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies. NICE technology appraisal guidance 1073
2025     National Institute for Health and Care Excellence (NICE) Sparsentan for treating primary IgA nephropathy. NICE technology appraisal guidance 1074
2025     National Institute for Health and Care Excellence (NICE) Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal). NICE technology appraisal guidance 1078
2025     Institute of Health Economics (IHE) PET/CT capacity for cancer diagnosis and follow-up: rapid review
2025     NIHR Health Services and Delivery Research programme Community and hospital-based healthcare professionals perceptions of digital advance care planning for palliative and end-of-life care: a latent class analysis
2025     NIHR Health Technology Assessment programme The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review
2025     Health Technology Wales (HTW) Smartphone based photoplethysmography for the detection and monitoring of atrial fibrillation
2025     NIHR Health Services and Delivery Research programme How lived experiences of illness trajectories, burdens of treatment, and social inequalities shape service user and caregiver participation in health and social care: a theory-informed qualitative evidence synthesis
2025     Agency for Care Effectiveness (ACE) Asciminib for Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase after two or more tyrosine kinase inhibitors
2025     Agency for Care Effectiveness (ACE) Atogepant and rimegepant for prophylaxis of migraine
2025     Agency for Care Effectiveness (ACE) Epcoritamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
2025     Agency for Care Effectiveness (ACE) Finerenone for treating chronic kidney disease and albuminuria associated with type 2 diabetes
2025     Agency for Care Effectiveness (ACE) Mavacamten for treating obstructive hypertrophic cardiomyopathy
2025     NIHR Health Services and Delivery Research programme Enhancing referrals to child and adolescent mental health services: the EN-CAMHS mixed-methods study
2025     NIHR Health Services and Delivery Research programme Barriers to and outcomes of unspecified kidney donation in the UK: BOUnD, a mixed-methods study
2025     NIHR Health Services and Delivery Research programme After the disruptive innovation: How remote and digital services were embedded, blended and abandoned in UK general practice – longitudinal study
2025     NIHR Health Services and Delivery Research programme The spiritual needs and care of children and young people with life-threatening or life-shortening conditions, and parents (SPARK): a mixed-method investigation
2025     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of detailed anomaly ultrasound screening in the first trimester: a mixed-methods study
2025     NIHR Health Technology Assessment programme Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trial
2025     NIHR Health Technology Assessment programme Effects of pharmacological and non-pharmacological interventions for the management of sleep problems in people with fibromyalgia: a multi-methods evidence synthesis
2025     National Institute for Health and Care Excellence (NICE) Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal). NICE technology appraisal guidance 1061
2025     National Institute for Health and Care Excellence (NICE) Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma. NICE technology appraisal guidance 1059
2025     National Institute for Health and Care Excellence (NICE) Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1060
2025     National Institute for Health and Care Excellence (NICE) Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor. NICE technology appraisal guidance 1062
2025     National Institute for Health and Care Excellence (NICE) Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment. NICE technology appraisal guidance 1063
2025     National Institute for Health and Care Excellence (NICE) Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 1064
2025     National Institute for Health and Care Excellence (NICE) Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 1065
2025     National Institute for Health and Care Excellence (NICE) Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 1068
2025     NIHR Health Services and Delivery Research programme Emergency medical services streaming enabled evaluation in trauma: the SEE-IT Feasibility RCT
2025     NIHR Health Services and Delivery Research programme Co-designing and testing the learn together guidance to support patient and family involvement in patient safety investigations: a mixed-methods study
2025     NIHR Health Technology Assessment programme Behaviour change interventions to promote physical activity in people with intermittent claudication: the OPTIMA systematic review
2025     NIHR Health Technology Assessment programme Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation
2025     NIHR Health Technology Assessment programme Sputum colour charts to guide antibiotic self-treatment of acute exacerbation of chronic obstructive pulmonary disease: the Colour-COPD RCT
2025     NIHR Health Services and Delivery Research programme Implementing routine assessment of perinatal anxiety: case studies
2025     NIHR Health Services and Delivery Research programme How to implement digital clinical consultations in UK maternity care: the ARM@DA Realist Review
2025     Health Information and Quality Authority (HIQA) Evidence review of specialist cardiac services
2025     Agency for Care Effectiveness (ACE) Deucravacitinib for moderate-to-severe chronic plaque psoriasis
2025     Agency for Care Effectiveness (ACE) Durvalumab in combination with tremelimumab for treating unresectable hepatocellular carcinoma
2025     Agency for Care Effectiveness (ACE) Glofitamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
2025     Agency for Care Effectiveness (ACE) Pembrolizumab for treating locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma
2025     Agency for Care Effectiveness (ACE) Pembrolizumab for treating resectable Stage II, IIIA, or IIIB (T3-4N2) non-small-cell lung cancer
2025     Agency for Care Effectiveness (ACE) Sacituzumab govitecan for unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer
2025     Agency for Care Effectiveness (ACE) Triple therapy inhalers for treating asthma or chronic obstructive pulmonary disease
2025     Agency for Care Effectiveness (ACE) Pneumococcal conjugate vaccines (15-valent and 20-valent) for the prevention of pneumococcal disease in adults
2025     NIHR Health Technology Assessment programme Bisoprolol for patients with chronic obstructive pulmonary disease at high risk of exacerbation: the BICS RCT
2025     NIHR Health Technology Assessment programme Effectiveness of biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: the BATCH RCT
2025     NIHR Health Technology Assessment programme Establishing the best step-up treatments for children with uncontrolled asthma despite inhaled corticosteroids: the EINSTEIN systematic review, network meta-analysis and cost-effectiveness analysis using individual participant data
2025     NIHR Health Technology Assessment programme Software with artificial intelligence-derived algorithms for detecting and analysing lung nodules in CT scans: systematic review and economic evaluation
2025     NIHR Health Technology Assessment programme Rapid tests to inform triage and antibiotic prescribing decisions for adults presenting with suspected acute respiratory infection: a rapid evidence synthesis of clinical effectiveness and cost–utility studies
2025     National Institute for Health and Care Excellence (NICE) Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B. NICE highly specialised technologies guidance 32
2025     National Institute for Health and Care Excellence (NICE) Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over. NICE highly specialised technologies guidance 33
2025     Agency for Care Effectiveness (ACE) Elastomeric infusion pumps for outpatient parenteral antimicrobial therapy
2025     Agency for Care Effectiveness (ACE) Deep brain stimulators for treatment of Parkinson disease, dystonia or essential tremor
2025     Agency for Care Effectiveness (ACE) Antibacterial envelope for implantable neurostimulator infection control
2025     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial
2025     NIHR Health Technology Assessment programme Technology-enabled CONTACT tracing in care homes in the COVID-19 pandemic: the CONTACT non-randomised mixed-methods feasibility study
2025     NIHR Health Technology Assessment programme Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and economic analysis
2025     Technology Assessment at SickKids (TASK) A micro-costing and cost consequence analysis from a randomized controlled trial comparing genome sequencing to exome sequencing for genetic diagnosis
2025     Agency for Care Effectiveness (ACE) EchoGo Heart Failure to aid in the diagnosis of heart failure with preserved ejection fraction
2025     Agency for Care Effectiveness (ACE) Fibresolve to aid in the diagnosis of idiopathic pulmonary fibrosis